Published in J Infect Dis on September 15, 2009
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Impaired humoral response to vaccines among HIV-exposed uninfected infants. Clin Vaccine Immunol (2011) 1.33
HIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents. Pediatr Infect Dis J (2012) 0.98
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr (2012) 0.92
Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis (2014) 0.91
Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine (2013) 0.89
Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. Hum Vaccin Immunother (2012) 0.89
GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. Open Virol J (2011) 0.78
Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection. Cochrane Database Syst Rev (2014) 0.78
HIV/HBV coinfection in children and antiviral therapy. Expert Rev Anti Infect Ther (2013) 0.78
Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco. BMC Public Health (2017) 0.75
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol (2007) 1.96
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS (2005) 1.71
HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology (2004) 1.70
Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine (1999) 1.65
Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine (2005) 1.44
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine (2000) 1.44
Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis (2005) 1.43
Immunization of HIV-infected children with varicella vaccine. J Pediatr (2001) 1.35
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine (1999) 1.27
Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine (2000) 1.23
Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis (2005) 1.18
Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology (1999) 1.15
Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis (2005) 1.14
Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med (2005) 1.10
Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics (2007) 1.10
Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J (2003) 1.08
Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J (2005) 1.03
Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis (2001) 1.02
Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis (2004) 1.02
Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics (2007) 1.00
Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine (2003) 0.99
Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health (2001) 0.97
Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine. BMC Infect Dis (2006) 0.95
Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine (2001) 0.95
Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. Pediatr Infect Dis J (2002) 0.93
Response to hepatitis B immunization by infants exposed to HIV. AIDS (1994) 0.87
Impaired response to hepatitis B vaccine in HIV infected children. Vaccine (1992) 0.87
Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine (2006) 0.87
Poor responses to recombinant HBV vaccination in patients with HIV infection. Trop Gastroenterol (2006) 0.85
HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression. Cytometry B Clin Cytom (2007) 0.85
Persistence of hepatitis B surface antibody levels after vaccination with a recombinant hepatitis B vaccine: a 3-year follow-up study. J Oral Sci (2000) 0.85
Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Med Virol (1995) 0.83
Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thai (2006) 0.83
Persistence of antibodies to the surface antigen of the hepatitis B virus (anti-HBs) in children subjected to the Expanded Programme on Immunization (EPI), including hepatitis-B vaccine, in Thailand. Ann Trop Med Parasitol (2000) 0.83
Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine (2006) 0.83
Antibody response to hepatitis B immunization in infants born to HIV-infected mothers. J Med Assoc Thai (2002) 0.83
Response of HIV/AIDS Patients to Hepatitis B Recombinant Vaccine. Braz J Infect Dis (1998) 0.82
Ten-year serological follow up of hepatitis B vaccine recipients. Indian J Gastroenterol (2000) 0.81
Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Pediatr (1994) 0.79
Antibody response to hepatitis B vaccine in infants of HIV-positive mothers. Int J Infect Dis (2002) 0.77
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol (2003) 5.43
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med (2015) 4.23
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics (2005) 3.42
Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics (2009) 3.32
Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96
Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. JAMA (2002) 2.93
Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med (2012) 2.77
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med (2010) 2.73
Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis (2008) 2.70
Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet (2013) 2.63
Validation of a 3-factor scoring model for the Pittsburgh sleep quality index in older adults. Sleep (2006) 2.62
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin (2009) 2.51
Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis (2009) 2.36
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain (2004) 2.15
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J (2009) 2.12
The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother (2012) 2.11
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain (2007) 2.08
Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet (2003) 2.04
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine (2007) 2.01
Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin Vaccine Immunol (2009) 2.00
Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis (2006) 1.99
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol (2010) 1.96
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev (2003) 1.95
The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ (2010) 1.88
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood (2012) 1.85
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81
Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc (2010) 1.76
Host-derived sialic acid is incorporated into Haemophilus influenzae lipopolysaccharide and is a major virulence factor in experimental otitis media. Proc Natl Acad Sci U S A (2003) 1.75
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin (2011) 1.73
Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics (2010) 1.72
DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis (2007) 1.71
Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis (2008) 1.70
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2013) 1.69
Otitis media and its consequences: beyond the earache. Lancet Infect Dis (2010) 1.68
Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J (2010) 1.67
Long-term assessment of T-cell populations in DiGeorge syndrome. J Allergy Clin Immunol (2003) 1.63
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr (2004) 1.60
The prevention and management of herpes zoster. Med J Aust (2008) 1.60
Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus. J Infect Dis (2007) 1.59
An evaluation of awareness: attitudes and beliefs of pregnant Nigerian women toward voluntary counseling and testing for HIV. AIDS Patient Care STDS (2007) 1.55
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS (2007) 1.53
Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis (2010) 1.52
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses (2010) 1.47
Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service. Clin Infect Dis (2009) 1.46
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin (2011) 1.46
Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med (2004) 1.44
Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73: 147-157. 1993. J Immunol (2008) 1.44
Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med (2010) 1.43
A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol (2009) 1.42
Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J (2012) 1.41
Severity of invasive pneumococcal disease in children caused by susceptible and nonsusceptible isolates. Pediatr Infect Dis J (2014) 1.40
Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq. Vaccine (2009) 1.40
Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics (2005) 1.39
Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry (2008) 1.38
Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics (2003) 1.37
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J (2005) 1.34
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
Carried pneumococci in Massachusetts children: the contribution of clonal expansion and serotype switching. Pediatr Infect Dis J (2011) 1.28
Role of complement in defense of the middle ear revealed by restoring the virulence of nontypeable Haemophilus influenzae siaB mutants. Infect Immun (2006) 1.25
HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites. J Infect Dis (2009) 1.24
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci U S A (2013) 1.23
Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study. Horm Res Paediatr (2011) 1.23
Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J (2002) 1.22
A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine (2010) 1.22
A prospective study of the herpes zoster severity of illness. Clin J Pain (2010) 1.22
Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo. Antimicrob Agents Chemother (2002) 1.20
Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J Virol (2005) 1.19
Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother (2004) 1.18
Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis (2005) 1.18
VZV T cell-mediated immunity. Curr Top Microbiol Immunol (2010) 1.17
Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice. J Clin Invest (2012) 1.16
HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS (2006) 1.15
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis (2010) 1.14
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine (2011) 1.14
Bone mineral density in children and adolescents with perinatal HIV infection. AIDS (2013) 1.13
Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine (2010) 1.12
Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era. BMC Infect Dis (2009) 1.11
Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages. J Immunol (2004) 1.11
Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. Am J Epidemiol (2013) 1.09
Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. J Allergy Clin Immunol (2009) 1.09
Role of complement in host defense against pneumococcal otitis media. Infect Immun (2009) 1.09